YayaNews LogoYaya Financial News
美股Neutral$KPTI

Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook

Karyopharm (KPTI) Q2 results: GAAP EPS -$2.32 miss, revenue $33.43M beats (-11.9% Y/Y), cash $65.4M.

Financial news writer2 ViewsSource Seeking Alpha

YayaNews contributes financial news and market context through the YayaNews editorial workflow.

Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook
Image Source: Seeking Alpha

Karyopharm (KPTI) Q2 results: GAAP EPS -$2.32 miss, revenue $33.43M beats (-11.9% Y/Y), cash $65.4M.

Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook | Seeking Alpha

Karyopharm Therapeutics

press release

(

KPTI

): Q2 GAAP EPS of -$2.32

misses by $0.90

.

Revenue of $33.43M (-11.9% Y/Y)

beats by $1.21M

.

Cash position: Cash, cash equivalents, restricted cash and investments as of June 30, 2026, totaled $65.4 million.

The company

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Recommended For You

More

Trending News

See More

»

Disclaimer

Original YayaNews editorial coverage, published for informational purposes.

This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.

Share

Topics & Symbols

Topics & symbols

Continue Reading

Previous & next

Related Reading

Go to Channel